MX2022006439A - Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva. - Google Patents

Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva.

Info

Publication number
MX2022006439A
MX2022006439A MX2022006439A MX2022006439A MX2022006439A MX 2022006439 A MX2022006439 A MX 2022006439A MX 2022006439 A MX2022006439 A MX 2022006439A MX 2022006439 A MX2022006439 A MX 2022006439A MX 2022006439 A MX2022006439 A MX 2022006439A
Authority
MX
Mexico
Prior art keywords
neovascularization
compounds
treatment
diseases associated
eye diseases
Prior art date
Application number
MX2022006439A
Other languages
English (en)
Spanish (es)
Inventor
Joel Kaye
Helena Eriksson
Marie Törngren
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of MX2022006439A publication Critical patent/MX2022006439A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022006439A 2019-12-19 2020-12-18 Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva. MX2022006439A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19218062 2019-12-19
EP20156158 2020-02-07
PCT/EP2020/086993 WO2021123142A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Publications (1)

Publication Number Publication Date
MX2022006439A true MX2022006439A (es) 2022-07-19

Family

ID=74141502

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006439A MX2022006439A (es) 2019-12-19 2020-12-18 Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva.

Country Status (15)

Country Link
US (2) US11478465B2 (https=)
EP (2) EP3886858B1 (https=)
JP (1) JP7730816B2 (https=)
KR (1) KR20220118419A (https=)
CN (1) CN114845718B (https=)
AU (1) AU2020408179B2 (https=)
BR (1) BR112022009192A2 (https=)
CA (1) CA3157394A1 (https=)
DK (1) DK3886858T3 (https=)
ES (1) ES2921360T3 (https=)
IL (1) IL293469B2 (https=)
MX (1) MX2022006439A (https=)
PL (1) PL3886858T3 (https=)
WO (1) WO2021123142A1 (https=)
ZA (1) ZA202204939B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3886946A1 (en) 2019-06-05 2021-10-06 Regeneron Pharmaceuticals, Inc. Devices and methods for precision dose delivery
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물
PL4312986T3 (pl) 2021-04-01 2025-02-17 Active Biotech Ab Preparat lakwinimodu do stosowania do oczu
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn
CN117256554A (zh) * 2023-09-08 2023-12-22 益诺思生物技术南通有限公司 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法
KR102925647B1 (ko) * 2023-10-13 2026-02-11 재단법인 대구경북첨단의료산업진흥재단 안질환 치료제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2012006538A1 (en) * 2010-07-09 2012-01-12 Teva Pharmaceutical Industries Ltd. Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
IN2014MN00333A (https=) 2011-07-28 2015-09-25 Teva Pharma
US20150111833A1 (en) * 2012-04-20 2015-04-23 Howard University Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease
EP2849762A4 (en) 2012-05-16 2016-02-24 Aadigen Llc MULTI-TARGET MODULATION FOR TREATING FIBROSIS AND INFLAMMATORY DISORDERS
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
MX373894B (es) * 2012-11-08 2020-07-09 Clearside Biomedical Inc Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos.
CN109432073A (zh) 2013-01-08 2019-03-08 帕萨罗杰卡有限公司 Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
EP3019526A1 (en) * 2013-07-11 2016-05-18 Novartis AG Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
WO2015060812A1 (en) 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
EP3068395A4 (en) 2013-11-15 2017-07-12 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
WO2017120355A1 (en) 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
CA3010862A1 (en) 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics
JP2020528082A (ja) * 2017-07-17 2020-09-17 ロイズマン,キース 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
KR20220118419A (ko) * 2019-12-19 2022-08-25 액티브 바이오테크 에이비 과도한 혈관신생과 관련된 안구 질병의 치료를 위한 화합물

Also Published As

Publication number Publication date
PL3886858T3 (pl) 2022-08-29
EP3886858B1 (en) 2022-05-11
ZA202204939B (en) 2023-12-20
US12208091B2 (en) 2025-01-28
EP4094765A1 (en) 2022-11-30
DK3886858T3 (da) 2022-08-22
ES2921360T3 (es) 2022-08-24
CN114845718A (zh) 2022-08-02
KR20220118419A (ko) 2022-08-25
IL293469A (en) 2022-08-01
CN114845718B (zh) 2025-05-16
CA3157394A1 (en) 2021-06-24
WO2021123142A1 (en) 2021-06-24
BR112022009192A2 (pt) 2022-07-26
EP3886858A1 (en) 2021-10-06
US20230066364A1 (en) 2023-03-02
US20210322400A1 (en) 2021-10-21
AU2020408179A1 (en) 2022-06-30
JP7730816B2 (ja) 2025-08-28
IL293469B1 (en) 2023-12-01
JP2023509336A (ja) 2023-03-08
US11478465B2 (en) 2022-10-25
AU2020408179B2 (en) 2025-04-10
IL293469B2 (en) 2024-04-01

Similar Documents

Publication Publication Date Title
MX2022006439A (es) Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva.
MX347226B (es) Tratamiento de enfermedad ocular.
MX2016009331A (es) Composiciones y metodos para tratar enfermedades oculares.
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
MX2021006092A (es) Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
MX2025004366A (es) Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro
AR052172A1 (es) Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares
SV2009003161A (es) Antagonistas de dii4 para el tratamiento de trastornos vasculares e isquemicos
UY33481A (es) Compuesto para el tratamiento de trastornos y enfermedades del segmento posterior ocular
CL2020001183A1 (es) Implantes de liberación sostenida para reducir la presión intraocular con duración prolongada del efecto.
MX2019013799A (es) Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo.
MY176525A (en) Therapeutic agent for ocular disease or prophylactic agent for ocular disease
PH12020551015A1 (en) Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability
AR062395A1 (es) Uso de derivados del 2.5-dihidroxibenceno para el tratamiento de enfermedades oculares
MX2018001918A (es) Aplicación cuantitativa periorbital de farmacos oftalmologicos.
ZA202309651B (en) Compositions and methods for treatment of ocular disease associated with angiogenesis
MX2022000928A (es) Proceso para la preparacion de suspensiones acuosas oftalmicas esteriles de nanocristales de la forma a de propionato de fluticasona.
MX2019011242A (es) Farmacos y composiciones para el tratamiento de trastornos oculares.
TN2016000259A1 (en) Salbutamol (albuterol) eye protective medicament.
RU2017133101A (ru) Пептиды для ингибирования ангиогенеза
MX376622B (es) Composicion farmaceutica oftalmologica.
EP4599889A3 (en) Sirna and their use in methods and compositions for inhibiting the expression of the nrarp gene
MX2023012826A (es) Tratamiento de enfermedades oculares utilizando antagonistas del receptor de endotelina.
MY198731A (en) Methods for treating ocular diseases
HK1231694A1 (en) Compositions and methods for treating ocular diseases